Business Wire

Thales Unveils New Secrets Management Solution to Help Reduce Risks and Improve DevOps and Cloud Security

24.4.2023 16:00:00 EEST | Business Wire | Press release

Share

Thales, the leading global technology and security provider, today announced the introduction of a new secrets management solution as part of its CipherTrust Data Security platform which unifies the discovery, classification, protection, and control of sensitive data across cloud, on-premises and hybrid environments. Thales’s new secrets management solution, powered by Akeyless’ Vault Platform, enables customers to manage and secure DevOps and cloud workloads’ secrets. The new capability enhances the capabilities of the CipherTrust Data Security platform to help security and governance teams reduce risks by streamlining security processes across their operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230424005088/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

@Thales

Thales’ new secrets management solution helps ensure that only authorized workloads and applications can access their passwords, API keys, and certificates, protecting them from unauthorized access, theft, or misuse. The process of secrets management typically involves generating and storing secrets securely, controlling access, and monitoring to alert when there is a suspicion of a breach and associated details.

Todd Moore, vice president of data security products at Thales: "Combining secrets management with key management is like having a fortified vault for all your valuable assets. We are pleased to meet our customers growing business needs by offering a single data security platform that can simplify the management of all their sensitive data, improve security and compliance, foster development collaboration, and scale their security infrastructure."

The addition of secrets management enables the CipherTrust Data Security Platform to solve several pain points for customers related to the storing and managing of secrets securely, including:

  • Mitigating the risk of data breaches: By providing secure storage and access control to sensitive data such as passwords, API keys, and certificates, which are valuable targets for attackers, it mitigates the risk of data breaches.
  • Simplifying the management of secrets: In many organizations, passwords and certificates are managed manually or with ad-hoc processes, which are time-consuming and error-prone, especially in large or complex environments.
  • Ensuring compliance with regulations and standards: Some industries and regions require compliance with specific regulations and standards for data security which could be very complex to navigate.
  • Enabling collaboration: Multiple teams or individuals who need access to secrets now have a centralized and secure way to collaborate on projects.

With support for secrets management, the CipherTrust Data Security Platform further simplifies customers' processes by allowing centralized management of secrets and keys and scaling up to encryption solutions and other data security use cases.

Shai Onn, President & Co-founder at Akeyless : “As enterprises increasingly adopt DevOps practices, Automation, containerization, and more cloud technologies, they face a new rising threat in the form of Secrets Sprawl, where credentials, certificates and keys of all forms are being found in large quantities within source code, configuration files, and DevOps automation platforms. In recent years, Akeyless has pioneered the SaaS based Secrets Management market, becoming the perfect choice for reputable enterprises globally, making it a natural partner for Thales. With Akeyless Vault Platform’s secrets management solution, Thales can offer a more holistic and cohesive platform for its customers enabling them to centralize and streamline their DevOps Security efforts, Cloud IAM initiatives and Encryption solutions projects.

For a demo, visit Thales’ booth #N-5369 and Akeyless.io’s booth #S-1861 at RSA 2023 (April 24 – 27 in San Francisco, USA) or learn more here.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfill their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 77,0001 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

PLEASE VISIT
Thales Group
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT
Thales, Media Relations
Security & Cybersecurity
Marion Bonnet
+33 (0)6 60 38 48 92
marion.bonnet@thalesgroup.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye